53525-60-3

Basic information

• Product Name: Ethyl 1-trityl-1H-imidazole-4-carboxylate
• Synonyms: 4-Carbethoxy-1-triphenylmethylimidazole
• CAS NO: 53525-60-3
• Molecular Formula: C₂₅H₂₂N₂O₂
• Molecular Weight: 382.47
• Product Categories: blocks;Carboxes;Imidazoles
• Mol File: 53525-60-3.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Ethyl 1-trityl-1H-imidazole-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 1-trityl-1H-imidazole-4-carboxylate(53525-60-3)
• EPA Substance Registry System: Ethyl 1-trityl-1H-imidazole-4-carboxylate(53525-60-3)

Safety Data

• Hazardous Substances Data: 53525-60-3(Hazardous Substances Data)

Usage

General Description

Ethyl 1-trityl-1H-imidazole-4-carboxylate is a chemical compound with the molecular formula C25H22N2O2. It is commonly used as an intermediate in the synthesis of pharmaceuticals and organic compounds. Ethyl 1-trityl-1H-imidazole-4-carboxylate is a derivative of imidazole, which is a five-membered heterocyclic ring containing nitrogen. The trityl group is a protecting group commonly used in organic synthesis to protect reactive functional groups. Ethyl 1-trityl-1H-imidazole-4-carboxylate has potential applications in medicinal chemistry and drug development, as well as in the production of other organic compounds. Due to its chemical structure, this compound may have interesting pharmacological properties and could be utilized in the development of new drug molecules.

InChI:InChI=1S/C25H22N2O2/c1-2-29-24(28)23-18-27(19-26-23)25(20-12-6-3-7-13-20,21-14-8-4-9-15-21)22-16-10-5-11-17-22/h3-19H,2H2,1H3

Upstream product

• 596-43-0 bromo-triphenyl-methane 
• 23785-21-9 ethyl 1H-imidazole-4-carboxylate 
• 76-83-5 trityl chloride 

Downstream Products

• 33769-07-2 4-(hydroxymethyl)-1-(triphenylmethyl)imidazole 
• 176721-02-1 4-<(2,3-dimethylphenyl)carbonyl>-1-(triphenylmethyl)imidazole 
• 191103-80-7 1H-1-triphenylmethylimidazole-4-carboxylic acid 

Relevant articles and documents

NAPHTHO[2,1 -D]THIAZOLE DERIVATIVES, COMPOSITIONS THEREOF AND METHODS OF TREATING DISORDERS

The present application relates to the compounds of formula (I) that inhibit CDK9, pharmaceutical compositions thereof and methods of making and using the same.

PREPARATION METHOD OF DEXMEDETOMIDINE INTERMEDIATE

The present invention discloses a preparation method of 2,3-dimethyl phenyl-1-trityl-imidazole-4-ketone. In accordance with this method, imidazole-4-ethyl formate is used as a raw material; ethyl formate is used for amino protection, 1-trityl-1H-imidazole

(SUBSTITUTED ARALKYL) HETEROCYCLIC COMPOUNDS

A (substituted-aralkyl)heterocyclic compound of the formula I wherein R1 is an azido, carbamoyl, cyano, formyl, hy-droxy or nitro radical, a 1-6C 1-hydroxyalkyl, alkoxy, alkylcarbamoyl, alkylthio, alkylsulphinyl or alkylsulphonyl radical, a 2-cyanoethyl radical, optionally bearing one to four 1-6C alkyl substituents, or a 2-6C alkanoyl, halogenoalkanoyl, alkanoyloxy, alkanoylamino, dialkylcarbamoyl or alkoxycarbonyl radical; R2 and R3, which may be the same or different, are each a hydrogen atom, a 1-6C alkyl, dueterioalkyl or halogenoalkyl radical, or a phenyl or phenyl(l-6C alkyl) radical, in each of which the phenyl may optionally bear one or more substituents; or R2 and R3, together with the carbon atom to which they are attached, may form a 3- to 6-membered ring; or R1R2R3C- is a 1,1-dicyanoethyl or trifluoromethylsulphonyl radical; R4 is a hydrogen or halogen atom, a cyano or nitro radical or a 1-6C alkyl or halogenoalkyl radical; R5 has any of the values de-fined above for the group RIR2R3C but is not necessarily the same as R1R2R3C, or has any of the values de-fined above for R4 but is not necessarily the same as R4, or is a carbamoyl, 1-pyrrolidinyl-carbonyl, piperidino-carbonyl, morpholinocarbonyl or nitro radical, a 1-6C alkoxy or halogenoalkoxy radical or a 2-6C alkanoyl or alkoxy-carbonyl radical; A is a methylene or ethylene radical optionally bearing one or more substituents selected from deuterium and halogen atoms, carbamoyl, cyano and hydroxy radicals, 1-6C alkyl and alkoxy radicals, and 2-6C alkanoyloxy radicals provided that when A is linked to R through a nitrogen atom thereof, it may not bear a hydroxy, alkoxy or alkanoyloxy sub-stituent on the carbon atom adjacent to such nitrogen atoms; and R6is a lH-l,2,4-triazol-l-yl, 4H-l,2,4-triazol-4-yl, IH-imidazol-1-yl, 5-cyano-lH-imidazol-l-yl, 3-pyridyl or 5-pyrimidinyl radical, or a IH-imidazol-1-yl radical, bearing at the 5-position thereof a 1-6C alkyl substituent which is itself optionally substituted by one or more carbamoyl, cyano, hydroxy or 2-6C alkoxycar-bonyl radicals; and provided that when R2, R3, R4 and R5 are hydrogen, A is a methylene radical and R6 is a 3-pyridyl radical, R1 is not a cyano, hydroxy or hydroxymethyl radical, and when R1 is a hydroxy radical, R3, R4 and R5 are hydrogen, A is a methylene radical and R6 is 3-pyridyl, R2 is not a methyl or a 2-chloro-1-methylethyl radical, and provided that when R1 is a methoxycarbonyl radical, R2, R3, R4 and R5 are hydrogen and A is a methylene radical, Ri is not a IH-imidazol-a1-yl radical; and the pharmaceutically acceptable acid addition salts thereof